Document:

EXHIBIT 10.1

 

AMENDMENT NO. 2 TO
JANUARY 3, 2008 LICENSE AGREEMENT

 

This Amendment No. 2 (hereinafter the “Amendment
No. 2”), entered into on May 15, 2015 (the “Amendment No. 2 Effective Date”) modifies and amends the License
Agreement dated January 3, 2008 (the “Agreement”), by and between Arno Therapeutics, Inc. located at 200 Route 31 North,
Suite 104, Flemington, New Jersey 08822 (“Company”) and Ohio State Innovation Foundation (“OSIF”) having
an address at 1524 N. High Street, Columbus, Ohio 43201.

 

BACKGROUND

 

OSIF and Company desire to amend the Agreement
in order to modify the specific terms of the Agreement to: (i) delete and replace definition of “IMPROVEMENTS” and
insert a structure-based definition of “ANALOGS” to include all permutations of “X”, “Ar”,
and “R” groups claimed in patents and patent applications listed in Appendix A, as amended herein; (ii) Update Appendix
A to include new patent applications and patents directed toward ANALOGS and OSU TechID 2013-135, “Novel p21 Activated Kinase
Inhibitors”; (iii) Grant certain first rights to Licensor’s rights in the field of “Aryl-pyrazole inventions”
made by the Inventor; (iv) document resolution of dispute between OSIF and Company; and (v) delete and replace definition of Net
Sales to better address altruistic sales for third world indications in developing countries. 

 

NOW THEREFORE, in consideration of the promises
and of the mutual covenants and agreements herein set forth, the parties hereto agree as follows:

 

1. Section 1.9 “IMPROVEMENTS”
of the Agreement is hereby deleted in its entirety and replaced with the following:

 

1.9 “IMPROVEMENTS” shall
mean Licensor’s rights in PATENT RIGHTS to:

(a) the composition of matter of LICENSED
PRODUCTS or ANALOGS made by the INVENTOR and formulations thereof,

(b) improved methods of manufacture
and production techniques of LICENSED PRODUCTS or ANALOGS,

(c) therapeutic indications and developments
intended to enhance the safety and efficacy of the LICENSED PRODUCTS or ANALOGS,

(d) methods of use, dosing, or
administration of LICENSED PRODUCTS or ANALOGS, and

(e) ANALOGS in patents and patent
applications claiming priority to U.S. Provisional Patent Applications 61/677,251 and 61/820,956 or resulting from a national stage
filing from WO 2014/022382 for all fields of use outside of prevention, treatment, or amelioration of a disease caused by a mycobacterium.

 

 

2. Section 1.27 is added to the Agreement
as follows:

 

			1.27 “ANALOG(S)” means any composition-of-matter (and racemates, polymorphs, and pharmaceutically acceptable salts,
co-crystals thereof) having the following structure:

 

 

    	 	 1  

                                                                                                                                                                                                                                                                                                                                                                                                                INFORMATION MARKED BY [***] HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.
	 

     

    

 

 

 

  

where:

X is selected from: alkyl
or haloalkyl, including but not limited to CF3;

 

Ar is selected from: phenyl,
biphenyl, naphthyl, anthryl, phenanthryl, fluorenyl, wherein Ar is optionally substituted with one or more substituents at any
suitable position, including but not limited to
and

 

	 	 	and 	 ;	 

 

 

R is
selected from: —CN, —CH2CN, —CH2CH2CN, —CH2CH2CH2CN,
-NH2

  

 

  

 

 

amioacetamide, guanidine, -NH-CO-(CH2)x>1-NH2

 

    	 	 2  

                                                                                                                                                                                                                                                                                                                                                                                                                INFORMATION MARKED BY [***] HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.
	 

     

    

 

;

 

 

R’
is selected from: SO2CH2CH2NH2, or SO2NH2 or
an amino acid attached through the α-carboxyl
group selected from the group consisting of L-Lys, D-Lys, β-Ala,
L-Leu, L-Ile, Phe, Asn, Glu and Gyl; 

 

R’’
is selected from: -H, methyl, ethyl, allyl, CH2CH2OH, CH2CN, CH2CH2CN, CH2CONH2,
and 

 

  

.

 

  

3. Appendix A is hereby deleted in its entirety
and replaced with Appendix A of this Amendment No. 2.

 

4. Section 1.28 is added to the Agreement
as follows:

 

1.28 “ARYL-PYRAZOLE INVENTIONS”
shall mean, collectively, any and all inventions owned or controlled by LICENSOR or under obligation of assignment to LICENSOR
that: (i) are not subject to any rights of a third party (other than the rights held by the U.S. Government as described in Section
2.5 of the License Agreement) in existence as of the Effective Date or the date of disclosure of such invention to LICENSOR or
The Ohio State University’s Office of Technology Commercialization (“TCO”); (iii) name as an inventor at least
one of any of the inventors listed on any patent and patent application listed in Appendix A, or are submitted by TCO or LICENSOR
to LICENSEE for consideration; and (iv) are directed toward any compositions of matter (or use or synthesis thereof or formulations
containing) that are not ANALOGS or LICENSED PRODUCTS under the January 3, 2008 License Agreement (as amended), such compositions
of matter having a structure as follows:

 

    	 	 3  

                                                                                                                                                                                                                                                                                                                                                                                                                INFORMATION MARKED BY [***] HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.
	 

     

    

 

 

.

 

 

5. Section 2.7 is added to the Agreement as
follows:

 

2.7 LICENSOR hereby grants to LICENSEE
a right of first review and first option to obtain an exclusive license, on the terms of the Patent &Technology License Agreement
attached hereto as Appendix B, to ARYL-PYRAZOLE INVENTIONS to make, have made, use, offer for sale, sell, import, export and otherwise
exploit products and services. LICENSOR agrees to promptly disclose each invention disclosure form describing ARYL-PYRAZOLE INVENTIONS
(each invention disclosure form for ARYL-PYRAZOLE INVENTIONS individually referred to as an “A-P IDF”) to LICENSEE.
LICENSEE agrees to review and share its perspectives and feedback on inventions described in each A-P IDF following disclosure
to LICENSEE (including an initial indication of interest in LICENSEE’s licensing of such invention(s) described in the A-P
IDF) within forty five (45) days after the disclosure to LICENSEE (such thirty (45) days referred to hereinafter as “Review
Period”). Upon written notice by LICENSEE, before expiration of the Review Period for a particular ARYL-PYRAZOLE INVENTION,
to LICENSOR of LICENSEE’s interest in licensing one of such ARYL-PYRAZOLE INVENTIONS, LICENSEE and LICENSOR shall have ninety
(90) days from the end of the Review Period for that ARYL-PYRAZOLE INVENTION to negotiate in good faith a license agreement to
that ARYL-PYRAZOLE INVENTION (“Negotiation Period”) on the terms of the Patent &Technology License Agreement attached
hereto as Appendix B. The parties acknowledge that any such license agreement to a particular ARYL-PYRAZOLE INVENTION may differ
in form and terms from the present Agreement. In the event that LICENSEE does not obtain a license with respect to a particular
ARYL-PYRAZOLE INVENTION during the Negotiation Period, LICENSOR shall not have any further obligation to LICENSEE with respect
to that particular ARYL-PYRAZOLE INVENTION and LICENSOR may license such particular ARYL-PYRAZOLE INVENTION to any third party
after expiration of the Negotiation Period.

 

6. Appendix B is added to the Agreement with
Appendix B of this Amendment No. 2.

 

7. Section 1.18 “NET SALES”
is deleted in its entirety and replaced with the following:

 

			1.18 “NET SALES” means the GROSS CONSIDERATION received by LICENSEE, AFFILIATES,
and SUBLICENSEES from the SALE of LICENSED PRODUCTS, less the following items directly attributable to the SALE of such LICENSED
PRODUCTS that are specifically identified on the invoice for such SALE and borne by the LICENSEE, AFFILIATES, or SUBLICENSEES as
the seller:

(a) discounts,
returns and allowances actually granted to customers;

(b) commissions
actually paid to third-party distributors and other third-party sales agencies;

(c) sales,
value added, use and other taxes and government charges actually paid, excluding income taxes;

(d) import
and export duties actually paid;

(e) bad debt
deductions actually written off during the accounting period;

(d) freight,
transport, packing and transit insurance charges actually paid or allowed; and

(e) other amounts
actually refunded, allowed or credited due to rejections or returns, but not exceeding the original invoiced amount.

 

    	 	 4  

                                                                                                                                                                                                                                                                                                                                                                                                                INFORMATION MARKED BY [***] HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.
	 

     

    

 

8. Section 1.29 is added to the
Agreement as follows:

			1.29 “GROSS CONSIDERATION” means all cash and non-cash consideration (e.g., securities).

 

9. Section 1.30 is added to the
Agreement as follows:

			1.30 “SALE” means any transfer or other disposition of LICENSED PRODUCTS or LICENSED PROCESSES for which consideration
is received by LICENSEE, its AFFILIATES or SUBLICENSEES. A SALE of LICENSED PRODUCTS or LICENSED PROCESSES will be deemed completed
at the time LICENSEE or its AFFILIATE or its SUBLICENSEE receives such consideration.

 

10. The parties additionally
agree as follows:

A dispute has arisen between Ohio
State Innovation Foundation (“OSIF”) and Arno Therapeutics, Inc. (“Arno”) regarding the interpretation
of the term IMPROVEMENTS and the scope of PATENT RIGHTS licensed under the License Agreement for Case No. 04021, “A Novel
Class of PDK-1/Akt Signaling Inhibitors” (the “Dispute”), which the parties now wish to resolve and settle. The
parties have agreed upon a revised definition of IMPROVEMENTS, as well as clarified the scope of the existing PATENT RIGHTS and
defined a framework that identifies the scope of IMPROVEMENTS that comprises the PATENT RIGHTS as well as the optional PATENT RIGHTS
in which Arno has the right of first look at certain other enhancements to the PATENT RIGHTS that are not classified as IMPROVEMENTS.

As a result of the parties’
resolution of the Dispute, each party hereby releases the other party (and any of their the parents, subsidiaries, agents, affiliates,
assigns, employees, owners, and successors-in-interest) from any and all claims, demands, liabilities, and causes of action, asserted
or unasserted, arising out of any act, error, omission, representation, agreement, circumstance or event arising from or associated
with the Dispute that arose prior to the date hereof, or otherwise occurring between OSIF and Arno prior to the date hereof, as
they relate to the Dispute, whether such claims are relate to the PATENT RIGHTS or IMPROVEMENTS, or are founded upon breach of
contract, tort, breach of duties of good faith and fair dealing, or breach of any other state or federal statutes or common law,
or any other related theory.

The parties further agree and acknowledge
that these releases shall not extend to any obligation arising from the License Agreement, nor shall they release any payment obligations
set forth therein not related to the Dispute.

Notwithstanding anything to the
contrary herein, LICENSOR warrants and represents that, to LICENSOR’s actual knowledge, the following have been disclosed
to LICENSEE:

		(1)	all patents and patent applications corresponding to LICENSED INFORMATION and PATENT RIGHTS, IMPROVEMENTS, ANALOGS, as amended,
to LICENSOR’s actual knowledge, are either: (i) included in Appendix A, as amended, or (ii) identified in Section 1.9(e)
of this Agreement, and

		(2)	all patents and patent applications corresponding to ARYL-PYRAZOLE INVENTIONS as of the Effective Date of this Amendment.

 

To the extent any additional inventions,
patents, and patent applications that correspond to PATENT RIGHTS, IMPROVEMENTS, ANALOGS, and ARYL-PYRAZOLE INVENTIONS are discovered
after the Effective Date of this Amendment, the LICENSE AGREEMENT, as amended, shall apply to any such rights.

Each party acknowledges that it
is executing this release entirely upon its own volition, individual judgment, belief and knowledge; that this release is made
without reliance upon any statement or representation of any party or any person not herein expressed; that no promise, inducement
or agreement, not herein expressed, has been made to it; that this release contains, and is, the entire agreement and understanding
between the parties referred to above, whether specifically named or not; and that the terms of this release are contractual and
not mere recitals.

The parties acknowledge they may
hereafter discover new facts different from or in addition to those they now know or believe to be true, but they agree to assume
the risk of the possible discovery of additional facts, and agree that this release will be and shall remain effective in all respects
regardless of the discovery of additional facts with respect to their claims arising out of the Dispute.

 

    	 	 5  

                                                                                                                                                                                                                                                                                                                                                                                                                INFORMATION MARKED BY [***] HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.
	 

     

    

 

Except as amended above, the terms and conditions
of the Agreement remain in full force and effect.

 

A facsimile or electronically scanned signature
will be deemed sufficient evidence of a Party’s execution of this Amendment. If this Amendment is executed first by OSIF
and is not executed by Company and received by OSIF within fifteen (15) days of the date of signature set forth under OSIF’s
signature below, then this Amendment shall be null and void and of no further effect.

 

AGREED:

  

 

	
        OHIO STATE
        INNOVATION FOUNDATION

         

        By: 
        /s/ Stan Micek

        Name: Stan
        Micek

        Title: President

        Date:  09 JUL 15

         

         

         

         
	 	
        ARNO THERAPEUTICS

         

        By: 
        /s/ Alexander Zukiwski

        Name: Alexander
        Zukiwski

        Title: CEO

        Date: 
        July 9, 2015

         

         

         

 

    	 	 6  

                                                                                                                                                                                                                                                                                                                                                                                                                INFORMATION MARKED BY [***] HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.
	 

     

    

 

Appendix A

 

	Title of Application/Patent	Tech ID	Application Type	Filing Date	Serial No.	Grant No.	Grant Date	Country	Status
	 
	PDK-1/AKT SIGNALING INHIBITORS	2004-021	EPC	10/4/2004	4816902.3	1696907	4/17/2013	Austria	Issued 
	PDK-1/AKT SIGNALING INHIBITORS	2004-021	EPC	10/4/2004	4816902.3	1696907	4/17/2013	Belgium	Issued 
	PDK-1/AKT SIGNALING INHIBITORS 	2004-021	PCT 	10/04/2004 	2566846 	2566846 	08/28/2012 	Canada 	Issued 
	PDK-1/AKT SIGNALING INHIBITORS 	2004-021	PCT 	10/04/2004 	200480036007.3 	ZL200480036007.3	6/16/2010	China 	Issued 
	PDK-1/AKT SIGNALING INHIBITORS	2004-021	EPC	10/4/2004	4816902.3	1696907	4/17/2013	Denmark	Issued 
	PDK-1/AKT SIGNALING INHIBITORS 	2004-021	PCT 	10/04/2004 	04816902.3 	1696907	4/17/2013	Europe 	Inactive 
	PDK-1/AKT SIGNALING INHIBITORS 	2004-021	EPC	10/04/2004 	04816902.3 	1696907	4/17/2013	Finland	Issued 
	PDK-1/AKT SIGNALING INHIBITORS 	2004-021	EPC	10/04/2004 	04816902.3 	1696907	4/17/2013	France	Issued 
	PDK-1/AKT SIGNALING INHIBITORS 	2004-021	EPC	10/04/2004 	04816902.3 	1696907	4/17/2013	Germany	Issued 
	PDK-1/AKT SIGNALING INHIBITORS	2004-021	EPC	10/4/2004	4816902.3	1696907	4/17/2013	Hungary	Issued 
	PDK-1/AKT SIGNALING INHIBITORS 	2004-021	PCT 	10/04/2004 	1131/CHENP/2006 	 	 	India 	Patent Pending 
	PDK-1/AKT SIGNALING INHIBITORS 	2004-021	EPC	10/04/2004 	04816902.3 	1696907	4/17/2013	Ireland	Issued 
	PDK-1/AKT SIGNALING INHIBITORS 	2004-021	EPC	10/04/2004 	04816902.3 	1696907	4/17/2013	Italy	Issued 
	PDK-1/AKT SIGNALING INHIBITORS 	2004-021	PCT 	10/04/2004 	2006-534245 	4745971	05/20/2011 	Japan 	Issued 
	PDK-1/AKT SIGNALING INHIBITORS 	2004-021	PCT 	10/04/2004 	10-2006-7008622 	1217427	12/24/2012	Korea, South 	Issued 
	PDK-1/AKT SIGNALING INHIBITORS 	2004-021	EPC	10/04/2004 	04816902.3 	1696907	4/17/2013	Luxembourg	Issued 
	PDK-1/AKT SIGNALING INHIBITORS 	2004-021	EPC	10/04/2004 	04816902.3 	1696907	4/17/2013	Monaco	Issued 
	PDK-1/AKT SIGNALING INHIBITORS 	2004-021	EPC	10/04/2004 	04816902.3 	1696907	4/17/2013	Netherlands	Issued 

 

    	 	 
INFORMATION MARKED BY [***] HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

	 

     

    

 

 

 

	PDK-1/AKT Signaling Inhibitors 	2004-021	PCT 	10/04/2004 	PCT/US2004/032723 	 	 	PCT (Not Applicable) 	Inactive 
	PDK-1/AKT Signaling Inhibitors 	2004-021	PCT 	10/04/2004 	200602174-5 	120,841 	07/31/2007 	Singapore 	Issued 
	PDK-1/AKT SIGNALING INHIBITORS 	2004-021	EPC	10/04/2004 	04816902.3 	1696907	4/17/2013	Slovenia	Abandoned 
	PDK-1/AKT SIGNALING INHIBITORS 	2004-021	EPC	10/04/2004 	04816902.3 	1696907	4/17/2013	Spain	Issued 
	PDK-1/AKT SIGNALING INHIBITORS 	2004-021	EPC	10/04/2004 	04816902.3 	1696907	4/17/2013	Sweden	Issued 
	PDK-1/AKT SIGNALING INHIBITORS 	2004-021	EPC	10/04/2004 	04816902.3 	1696907	4/17/2013	Switzerland	Issued 
	PDK-1/AKT SIGNALING INHIBITORS 	2004-021	EPC	10/04/2004 	04816902.3 	1696907	4/17/2013	United Kingdom	Issued 
	PDK-1/AKT Signaling Inhibitors 	2004-021	Utility 	10/04/2004 	10/957,925 	 	 	United States of America 	Abandoned 
	PDK-1/AKT SIGNALING INHIBITORS 	2004-021	Provisional 	10/08/2003 	60/509,814 	 	 	United States of America 	Expired 
	PDK-1/AKT SIGNALING INHIBITORS 	2004-021	Continuation Application 	09/28/2007 	11/864,612 	7,576,116 	08/18/2009 	United States of America 	Issued 
	PDK-1/AKT SIGNALING INHIBITORS 	2004-021	Divisional 	05/12/2008 	12/118,788 	8,541,460	9/24/2013	United States of America 	Issued 
	PDK-1/AKT SIGNALING INHIBITORS 	2004-021	Divisional 	06/02/2009 	12/476,772 	8,546,441	10/1/2013	United States of America 	Issued 
	PDK-1/AKT SIGNALING INHIBITORS 	2004-021	Utility 	09/23/2010 	12/888,687 	8,080,574 	12/20/2011 	United States of America 	Issued 
	PDK-1/AKT SIGNALING INHIBITORS 	2004-021	Divisional 	12/19/2011 	13/329,646 	 	 	United States of America 	Abandoned 
	 
	Novel small-molecule autophagy-inducing agents as anti-infective agents against intracellular pathogens 	2007-088	Provisional 	07/24/2007 	60/951,672 	 	 	United States of America 	Expired
	Anti-infective agents against itracellular pathogens 	2007-088	Provisional 	07/26/2007 	60/952,158 	 	 	United States of America 	Expired

 

 

    	 	 
INFORMATION MARKED BY [***] HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

	 

     

    

 

 

	Anti-infective agents against itracellular pathogens 	2007-088	Utility	07/24/2008 	12/179,134 	8,039,502 	10/18/2011 	United States of America 	Issued 
	ANTI-INFECTIVE AGENTS AGAINST INTRACELLULAR PATHOGENS (D1) 	2007-088	Divisional 	10/07/2011 	13/267,943 	8,445,483	5/21/2013	United States of America 	Issued 
	ANTI-INFECTIVE AGENTS AGAINST INTRACELLULAR PATHOGENS (D2) 	2007-088	Divisional 	4/24/2013	13/869,386	8,741,944	4/24/2013	United States of America 	Issued 
	 
	Anti-Francisella Agents	2009-077	Priority	4/22/2009	12/428,035	 	 	United States of America	Abandoned
	Anti-Francisella Agents	2009-077	ORD	5/25/2010	10005407.1	2246332	3/18/2013	Europe	Inactive
	Anti-Francisella Agents	2009-077	EPC	5/25/2010	10005407.1	2246332	3/18/2013	Germany	Issued
	Anti-Francisella Agents	2009-077	EPC	5/25/2010	10005407.1	2246332	3/18/2013	Italy	Issued
	Anti-Francisella Agents	2009-077	EPC	5/25/2010	10005407.1	2246332	3/18/2013	Spain	Issued
	Anti-Francisella Agents	2009-077	EPC	5/25/2010	10005407.1	2246332	3/18/2013	Switzerland	Issued
	Anti-Francisella Agents	2009-077	EPC	5/25/2010	10005407.1	2246332	3/18/2013	United Kingdom	Issued
	Anti-Francisella Agents	2009-077	Divisional	9/12/2012	13/610,967	8,580,827	11/12/2013	United States of America	Issued
	 	 	 	 	 	 	 	 	 
	Anti-Staphylococcal Celecoxib Derivatives	2011-039	Provisional	11/1/2010	61/408,680	 	 	United States of America	Expired
	Anti-Staphylococcal Celecoxib Derivatives	2011-039	PCT	10/31/2011	PCT/US11/058501	 	 	PCT	Inactive
	Anti-Staphylococcal Celecoxib Derivatives	2011-039	PCT	6/1/2013	11838597	 	 	Europe	Published
	Anti-Staphylococcal Celecoxib Derivatives	2011-039	PCT	5/1/2013	13/882,897	 	 	United States of America	Allowed
	 	 	 	 	 	 	 	 	 

 

    	 	 
INFORMATION MARKED BY [***] HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

	 

     

    

 

 

	Anticancer Multikinase Inhibitors	2013-135	Provisional	3/29/2003	61/806,518	 	 	United States of America	Expired
	Anticancer P21-Activated Kinase Inhibitors	2013-135	Utility	3/31/2014	14/230,689	 	 	United States of America	Published
	 	 	 	 	 	 	 	 	 
	The following are included in the definition of PATENT RIGHTS to the extent these cover ANALOGS claiming priority to US Provisional Patent Applications 61/677,251 and 61/820,956 or resulting from a national stage filing from WO2014/022382 for all fields of use outside of prevention, treatment or amelioriation of a disease caused by a mycobacterium:
	Antibacterial Protein Kinase Inhibitors	2013-339	Provisional	7/30/2012	61/677,251	 	 	United States of America	Expired
	Antibacterial Protein Kinase Inhibitors	2013-339	Provisional	5/8/2013	61/820,956	 	 	United States of America	Expired
	Antibacterial Protein Kinase Inhibitors	2013-339	PCT	7/30/2013	PCT/US2013/052706	 	 	PCT	Inactive
	Antibacterial Protein Kinase Inhibitors	2013-339	PCT	2/17/2015	2013296619	 	 	Australia	Pending
	Antibacterial Protein Kinase Inhibitors	2013-339	PCT	3/2/2015	BR1120150020780	 	 	Brazil	Pending
	Antibacterial Protein Kinase Inhibitors	2013-339	PCT	awaiting filing date	awaiting serial no.	 	 	Canada	Pending
	Antibacterial Protein Kinase Inhibitors	2013-339	PCT	awaiting filing date	awaiting serial no.	 	 	China	Pending
	Antibacterial Protein Kinase Inhibitors	2013-339	PCT	2/4/2015	13825373.7	 	 	Europe	Pending
	Antibacterial Protein Kinase Inhibitors	2013-339	PCT	1/29/2015	awaiting serial no.	 	 	Japan	Pending
	Antibacterial Protein Kinase Inhibitors	2013-339	PCT	2/10/2015	10-2015-7003562	 	 	South Korea	Pending
	Antibacterial Protein Kinase Inhibitors	2013-339	PCT	1/29/2015	14/418,250	 	 	United States of America	Pending
	 	 	 	 	 	 	 	 	 

  

    	 	 
INFORMATION MARKED BY [***] HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

	 

     

    

APPENDIX
B

PATENT &
Technology LICENSE AGREEMENT

AGT.
No.  ____________

 

This Patent & Technology
License Agreement (“PTLA”) is by and between the Licensor and the Licensee identified below (collectively, “Parties”,
or singly, “Party”).

 

Licensor owns, controls
and/or has the right to sublicense the Licensed Subject Matter (defined in Exhibit A). Licensee desires to secure the right and
license to use, develop, manufacture, market, and commercialize the Licensed Subject Matter. Licensor desires to have the Licensed
Subject Matter developed and used for the benefit of Licensee, the inventors, Licensor, and the public.

 

NOW, THEREFORE, in consideration
of the mutual covenants and promises herein contained, the Parties hereby agree as follows:

 

The Terms and Conditions
of this PTLA attached hereto as Exhibit A are incorporated herein by reference in their entirety (the “Terms and Conditions”).
In the event of a conflict between provisions of this PTLA and the Terms and Conditions, the provisions in this PTLA shall govern.
Unless defined in this PTLA, capitalized terms used in this PTLA shall have the meanings given to them in the Terms and Conditions.
The section numbers used in the left hand column in the table below correspond to the section numbers in the Terms and Conditions.

 

	1.                                                                                  Definitions
	 	Effective
    Date	[to be determined by the parties prior to execution] 
	Licensor	Ohio State Innovation Foundation, with an address at 1524 North High Street, Columbus, OH 43201.
	
        Licensee 
	Arno Therapeutics, a Delaware corporation, with its principal place of business at 200 Route 31 North, Suite 104, Flemington, New Jersey 08822
	Territory
    	Worldwide
	
        Field of Use

         
	
        Field of Use: All fields

         

	Patent
    Rights/Technology Rights [to be determined by the parties prior to execution]
	
        App. No./

        

        Date of Filing

        
	Title	Inventor(s)	Jointly
    Owned? (Y/N; if Y, with whom?)	Prosecution
    Counsel
	
        [App
number]  [Filing
date]

        [Tech ID] 
	[Title of patent or Technology]	[Inventor name(s)]	
         ̈ Yes,

        w/
[whom] 

         ̈
No
	[Law firm]
	[App number]  [Filing date] [Tech ID]	[Title of patent or Technology]	[Inventor name(s)]	
         ̈ Yes,

        w/[whom]

         ̈
        No

         
	[Law firm]
	 	 	 	 	 	 	 

 

	{00258124-1}Licensee: Arno Therapeutics, Inc.	CONFIDENTIAL	Exclusive License (Non-Equity)
	Licensor: Ohio State Innovation Foundation	 	Page 1 of 25
	 		

    	 	 
INFORMATION MARKED BY [***] HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

	 

     

    

 

 

	Diligence
    Milestones, Fees and Deadlines 
	
         

         

        2.4, 3

         
	Milestone Events	Milestone Fees   Due by the Quarterly Payment Deadline for the Contract Quarter in which the milestone events are achieved.	Deadlines
	1. [***]	[***]	
        [***]

	2. [***]	[***]	
        [***]

         

	3. [***]	[***]	
        To be determined by the parties prior to execution

	4. [***]	[***]	 
	5. [***]	[***]	 
	6. [***]	[***]	 
	 	7. [***]	[***]	 
	 	8. [***]	[***]	 

	Compensation
	3	Patent
    expenses due upon Effective Date	Current
    estimated amount. Licensee’s obligations to pay all past and future patent expenses
    pursuant to Section 6 (Patent Expenses and Prosecution) will not be limited by such amount.	
        Based on invoices received and approved as of:
[Date]

         

	$To be determined by the parties prior to execution
	3	Upfront
    Fee	$[***] due upon Effective Date
	3	License
    Maintenance Fees 	
        $[***]
due on 30 days after first anniversary of Effective Date

        $[***]
        due on each anniversary of Effective Date thereafter.

         

        Amounts paid as License Maintenance Fees shall be credited
against any Milestone Fees due in the same Contract Year as the Contract Year when the License Maintenance Fee is paid. No License
Maintenance Fees shall be due for Contract Years following the Contract Year when First Sale occurs.

         

 

 

	{00258124-1}Licensee: Arno Therapeutics, Inc.	CONFIDENTIAL	Exclusive License (Non-Equity)
	Licensor: Ohio State Innovation Foundation	 	Page 2  of 25
	 		

    	 	 
INFORMATION MARKED BY [***] HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

	 

     

    

 

	3	Sublicense
    Fees 	
        For Sublicense Agreements executed
        on or before the first anniversary of the Effective Date, [***]% of Non-Royalty Sublicensing
        Consideration, due on or before the Quarterly Payment Deadline for the Contract Quarter.

         

        For Sublicense Agreements executed
        after the first anniversary of the Effective Date and on or before the fourth anniversary of the Effective Date, [***]%
        of Non-Royalty Sublicensing Consideration, due on or before the Quarterly Payment Deadline for the Contract Quarter.

         

        For Sublicense Agreements
executed after the fourth anniversary of the Effective Date, [***]% of Non-Royalty Sublicensing
Consideration, due on or before the Quarterly Payment Deadline for the Contract Quarter.

         

	3.1	Running
    royalty rate (applies to Sales by Licensee, Affiliates and Sublicensees)	(a) Licensed Products and Licensed Processes covered by the Patent Rights	[***]%
	
        (b) Licensed Products and Licensed Processes not covered by
        the Patent Rights

         

         
	N/A
	3.1	Minimum
    Annual Royalties	
        $[***]
        for Contract Year ending December 31 of the Contract Year following the Contract Year when First Sale
        occurs,

         

        $[***]
        per Contract Year thereafter

         

	18.                                                                           Notices
	 	Licensee Contacts	 	Licensor Contacts
	
        Contact for Notice:

        Attn:
 [Name]

        [Address]

        Fax:
 [Fax number]

        Phone:
 [Phone number]

        E-mail:
         [E-mail]

          

        Accounting contact:

        Attn:
 [Name]

        [Address]

        Fax:
 [Fax number]

        Phone:
 [Phone number]

        E-mail:
         [E-mail]

          

        Patent prosecution contact:

        Attn:
 [Name]

        [Address] 

        Fax:
 [Fax number]

        Phone:
 [Phone number]

        E-mail:
         [E-mail]

         

         

         
	 	
        Contact for Notice:

        Attn: President

        1524 N. High Street

Columbus, OH 43201

        Fax: 614-292-8907

        Phone: 614-292-1315

        E-mail: innovation@osu.edu

          

        Payment and reporting contact:

        Checks payable to “Ohio State Innovation Foundation”

        Attn: Accounting/Compliance

        

        1524 N. High Street

Columbus, OH 43201 

        Fax: 614-292-8907

        

        Phone: 614-292-1315 

        E-mail: tcocompliance@osu.edu

         

        OSIF Patent Coordinator

        1524 N. High Street

Columbus, OH 43201

        Fax: 614-292-8907

        Phone: 614-292-1315

        E-mail: tcoip@osu.edu

         

         

        Patent prosecution contact:

        Attn:
 [Name]

        [Address]

        Fax:
 [Fax number]

        Phone:
 [Phone number]

        E-mail:
         [E-mail]

         

  

	{00258124-1}Licensee: Arno Therapeutics, Inc.	CONFIDENTIAL	Exclusive License (Non-Equity)
	Licensor: Ohio State Innovation Foundation	 	Page 3  of 25
	 		

    	 	 
INFORMATION MARKED BY [***] HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

	 

     

    

 

20. Special Provision.
The Parties hereby agree to the following special provisions (if any) set forth in this Section 20 with respect to this PTLA.

 

20.1 Definitions of FDA,
IND, Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial, NDA

 

“FDA” shall
mean the United States Food and Drug Administration or successor entity.

 

“IND” shall
mean an investigational new drug application filed with the FDA or corresponding regulatory agency outside of the U.S. prior to
the commencement of human clinical trials in the United States pursuant to 21 C.F.R. § 312(a) or pursuant to corresponding
regulations outside of the U.S..

 

“NDA” shall
mean an application for FDA approval or approval of corresponding regulatory agency outside of the U.S. to market a new drug filed
with the FDA pursuant to 21 C.F.R. § 312(a) or pursuant to corresponding regulations outside of the U.S..

 

“Phase I Clinical
Trial” shall mean the initial introduction of an investigational new drug into humans, the principal purpose of which is
to determine the metabolism and pharmacologic actions of the drug in humans, the side effects associated with increasing doses,
and, if possible, to gain early evidence on effectiveness, in compliance with 21 C.F.R. § 312(a).

 

“Phase II Clinical
Trial” shall mean controlled human clinical studies conducted to evaluate the effectiveness of a drug for a particular indication
or indications in patients with the disease or condition under study and to determine the common short-term side effects and risks
associated with the drug in compliance with 21 C.F.R. § 312(a).

 

“Phase III Clinical
Trial” shall mean expanded controlled and uncontrolled human clinical trials pursuant to a randomized study with endpoints
agreed upon by regulatory bodies for regulatory approval performed after Phase II Clinical Trials evidence suggesting effectiveness
of a drug has been obtained, and is intended to gather the additional information about effectiveness and safety that is needed
to evaluate the overall benefit-risk relationship of a drug and to provide an adequate basis for physician labeling, as in compliance
with 21 C.F.R. § 312(a).

 

21. No
Other Promises and Agreements; Representation by Counsel. Licensee expressly represents and warrants and does hereby state
and represent that no promise or agreement which is not herein expressed has been made to Licensee in executing this PTLA except
those explicitly set forth herein and in the Terms and Conditions, and that Licensee is not relying upon any statement or representation
of Licensor or its representatives. Licensee is relying on Licensee’s own judgment and has had the opportunity to be represented
by legal counsel. Licensee hereby represents and warrants that Licensee understands and agrees to all terms and conditions set
forth in this PTLA and said Terms and Conditions.

  

22. Deadline
for Execution by Licensee. If this PTLA is executed first by the Licensor and is not executed by the Licensee and received
by the Licensor at the address and in the manner set forth in Section 18 of the Terms and Conditions within thirty (30) days of
the date of signature set forth under the Licensor’s signature below, then this PTLA shall be null and void and of no further
effect.

 

 

	{00258124-1}Licensee: Arno Therapeutics, Inc.	CONFIDENTIAL	Exclusive License (Non-Equity)
	Licensor: Ohio State Innovation Foundation	 	Page 4  of 25
	 		

    	 	 
INFORMATION MARKED BY [***] HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

	 

     

    

 

IN WITNESS
WHEREOF, the Parties hereto have caused their duly authorized representatives to execute this PTLA.

 

	LICENSOR: OHIO STATE INNOVATION FOUNDATION	LICENSEE: ARNO THERAPEUTICS
	BY:	BY:
	NAME:  	NAME:
	TITLE:  	TITLE:
	DATE:	DATE: 

 

	{00258124-1}Licensee: Arno Therapeutics, Inc.	CONFIDENTIAL	Exclusive License (Non-Equity)
	Licensor: Ohio State Innovation Foundation	 	Page 5  of 25
	 		

    	 	 
INFORMATION MARKED BY [***] HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

	 

     

    

 

EXHIBIT
A

Terms and
Conditions of the PTLA

 

These Terms and Conditions of the PTLA
(“Terms and Conditions”) are incorporated by reference into the PTLA to which they are attached. All Section references
in these Terms and Conditions shall be references to provisions in these Terms and Conditions unless explicitly stated otherwise.

 

		1.	Definitions.

  

“Affiliate”
means any business entity more than 50% owned by Licensee, any business entity which owns more than 50% of Licensee, or any business
entity that is more than 50% owned by a business entity that owns more than 50% of Licensee.

  

“Agreement”
means collectively (i) these Terms and Conditions and (ii) the PTLA.

  

“Confidential
Information” means all information that is of a confidential and proprietary nature to Licensor or Licensee and
provided by one Party (“Discloser”) to the other Party (“Recipient”) under the Agreement.

  

“Contract
Quarter” means the three-month periods ending on March 31, June 30, September 30, and December 31 of each Contract
Year.

  

“Contract
Year” means the 12-month period ending on December 31.

  

“Effective
Date”, “Field of Use”, “Inventors”
(or singly, “Inventor”), “Licensee”,
“Licensor”, “Prosecution Counsel”, and “Territory” mean, respectively,
the date indicated as the Effective Date, the field indicated as the Field of Use, the inventor(s) identified in the definition
of Patent Rights/Technology Rights, the Party identified as the Licensee, the Party identified as the Licensor, the law firm or
attorney who is handling the prosecution of the Patent Rights, and the territory, all as identified in Section 1 of the PTLA.

  

“Government”
means any agency, department or other unit of the United States of America or the State of Ohio.

  

“Gross Consideration”
means all cash and non-cash consideration (e.g., securities).

  

“Licensed Process” means
a method, procedure, process, performance of a service, or other subject matter: (i) whose practice, use, sale, or offer for sale
is covered in whole or in part by a Valid Claim of the Patent Rights; and/or (ii) that uses, incorporates, is made with, is created
from, is derived or developed from the use of, or practices any (a) Technology Rights, (b) Licensed Products, and/or (c) modifications
of, enhancements to, and/or derivatives of the Technology Rights or Licensed Products.

 

“Licensed
Product” means any product, apparatus, kit, portion, part, or component thereof: (i) whose manufacture, use, sale,
offer for sale or import is covered in whole or in part by a Valid Claim of the Patent Rights; (ii) that uses, incorporates, is
made with, is created from, or is derived or developed from the use of, any Technology Rights; (iii) that is made by using a Licensed
Process or another Licensed Product; and/or (iv) that is derived or developed from a Licensed Process or another Licensed Product.

  

“Licensed Subject
Matter” means Patent Rights and/or Technology Rights.

 

	{00258124-1}Licensee: Arno Therapeutics, Inc.	CONFIDENTIAL	Exclusive License (Non-Equity)
	Licensor: Ohio State Innovation Foundation	 	EXHIBIT A
	 	Page 6  of 25	 
	 		

    	 	 
INFORMATION MARKED BY [***] HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

	 

     

    

 

“Milestone
Fees” means all fees identified as Milestone Fees in Sections 2.4 and 3 of the PTLA.

  

“Net
Sales” means the Gross Consideration received by Licensee, Affiliates, and Sublicensees from the Sale of Licensed
Products and Licensed Processes, less the following items directly attributable to the Sale of such Licensed Products that are
specifically identified on the invoice for such Sale and borne by the Licensee, Affiliates, or Sublicensees as the seller: (a)
discounts and rebates actually granted; (b) sales, value added, use and other taxes and government charges actually paid, excluding
income taxes; (c) import and export duties actually paid; (d) freight, transport, packing and transit insurance charges actually
paid or allowed; and (e) other amounts actually refunded, allowed or credited due to rejections or returns, but not exceeding the
original invoiced amount.

 

“Non-Royalty
Sublicensing Consideration" means the Gross Consideration received by the Licensee or its Affiliate directly or indirectly,
from any Sublicensee that is not an earned royalty, including but not limited to any fixed fee, option fee, distribution fee, license
fee, maintenance fee, milestone payment, unearned portion of any minimum royalty payment, equity, joint marketing fee, intellectual
property cross license, research and development funding in excess
of Licensee’s cost of performing such research and development, and any other property, consideration or thing of value given
or exchanged for a Sublicense Agreement regardless of how the Licensee and Sublicensee characterize such payments or consideration.

 

“PTLA”
means the particular Patent & Technology License Agreement to which these Terms and Conditions are attached and incorporated
into by reference.

 

“Patent
Rights” means the Licensor’s rights in: (a) the patents
and patent applications listed in Section 1 of the PTLA; (b) all provisional patent applications filed within one year of any
provisional application listed in Section 1 of the PTLA that can be included in a priority claim in a non-provisional application
claiming priority to any non-provisional application listed in Section 1 of the PTLA; (c) all non-provisional patent applications
that claim priority to any of the provisional applications
listed in Section 1 of the PTLA to the extent the claims of such non-provisional applications are entitled to claim priority
to such provisional applications; (d) all divisional(s), continuation(s) and continuations-in-part
(excluding new matter and claims containing new matter) of the non-provisional
patent applications identified in (a) and (b) and (c) above, to the extent that claims of such continuations-in-part are
entitled to claim priority to at least one of the patent applications
identified in (a) or (b) or (c) above; (e) all reissues, reexaminations, extensions, and foreign counterparts
of any of the patents or patent applications identified in (a), (b), (c) or (d), above; and (f) any patents that issue
with respect to any of the patent applications
listed in (a), (b) , (c), (d) or (e), above.

  

“Quarterly
Payment Deadline” means the day that is thirty (30) days after the last day of any particular Contract Quarter.

  

“Sell, Sale
or Sold” means any transfer or other disposition of Licensed Products or Licensed Processes for which consideration
is received by Licensee, its Affiliates or Sublicensees. A Sale of Licensed Products or Licensed Processes will be deemed completed
at the time Licensee or its Affiliate or its Sublicensee receives such consideration.

 

 

	{00258124-1}Licensee: Arno Therapeutics, Inc.	CONFIDENTIAL	Exclusive License (Non-Equity)
	Licensor: Ohio State Innovation Foundation	 	EXHIBIT A
	 	Page 7  of 25	 
	 		

    	 	 
INFORMATION MARKED BY [***] HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

	 

     

    

 

“Sublicense
Agreement” means any agreement or arrangement pursuant to which Licensee (or an Affiliate or Sublicensee) grants
to any third party any of the license or sublicense rights granted to the Licensee under the Agreement.

 

“Sublicense
Fee” means the fee specified in Section 3 of the PTLA.

  

“Sublicensee”
means any entity that enters into an agreement or arrangement with Licensee, or receives a sublicense grant from Licensee under
the Licensed Subject Matter, to manufacture, have manufactured, offer for sale, sell, lease, use, practice, and/or import the Licensed
Product and/or Licensed Process.

  

“Technology
Rights” means Licensor’s rights in technical information, know-how, processes, procedures, compositions, devices,
methods, formulas, protocols, techniques, designs, drawings or data created before the Effective Date by Inventors while employed
at The Ohio State University (“OSU”) and within the Field of Use which are not covered by Patent Rights, but which
are either (1) directly related to the Tech ID listed in Section 1 of the PTLA or (2) necessary or used for practicing inventions
claimed in patents and/or patent applications listed in the definition of Patent Rights whether outstanding, expired or abandoned.

  

“Valid Claim” means any
issued claim of the Patent Rights that has not expired, or been finally held as invalid or unenforceable by a court or administrative
body of competent jurisdiction from which no appeal can be or is taken, as well as any pending claim of the Patent Rights that
has not been finally and conclusively rejected from which no appeal can be or is taken.

 

		2.	License Grant and Commercialization.

  

		2.1	Grant.

 

		(a)	Licensor grants to Licensee a royalty-bearing exclusive license under Patent Rights to make, have
made, distribute, have distributed, use, offer for Sale, Sell, lease, loan and/or import Licensed Products and Licensed Processes
in the Field of Use in the Territory.

  

		(b)	Licensor grants to Licensee a royalty-bearing nonexclusive sublicense under Technology Rights to
make, have made, distribute, have distributed, use, offer for Sale, Sell, lease, loan and/or import Licensed Products and Licensed
Processes in the Field of Use in the Territory.

  

		(c)	This
                                         grant is subject to: (1) the payment by Licensee to Licensor of all consideration
                                         required under the Agreement; (2) any rights of, or obligations to, the Government; and
                                         (3) rights retained by Licensor to (i) publish the scientific findings from research
                                         related to the Licensed Subject Matter, (ii) use the Licensed Subject Matter for teaching,
                                         research, education, and other educationally-related purposes, and (iii) grant
                                         rights to, and transfer material embodiments of, the Licensed Subject Matter to other
                                         academic institutions or non-profit research institutions under a material transfer agreement
                                         substantially similar to the agreement of Attachment [x] (“Material Transfer Agreement”)
                                         for the purposes identified in clauses (i) and (ii) above provided that any such Transferee
                                         agrees to be bound by the applicable terms and conditions of this Agreement and shall
                                         indicate that Licensor is a third-party beneficiary of the Material Transfer Agreement.

 

	{00258124-1}Licensee: Arno Therapeutics, Inc.	CONFIDENTIAL	Exclusive License (Non-Equity)
	Licensor: Ohio State Innovation Foundation	 	EXHIBIT A
	 	Page 8  of 25	 
	 		

    	 	 
INFORMATION MARKED BY [***] HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

	 

     

    

 

		(d)	Licensor reserves all rights not expressly granted in the Agreement including, but not limited
to, any other licenses, implied or otherwise, to any patents or other rights of Licensor, regardless of whether such patents or
other rights are dominant or subordinate to any rights expressly granted in the Agreement, or are required to exploit any rights
expressly granted in the Agreement.

 

		2.2	Affiliates. Licensee may extend the license granted herein to any Affiliate provided
that the Affiliate agrees in writing to be bound by the Agreement to the same extent as Licensee.  For the sake of clarity,
any specific reference to “Licensee” herein shall include such Affiliate regardless of whether a specific reference
to an “Affiliate” is made in such provision. Licensee agrees to deliver such written agreement to Licensor within thirty
(30) calendar days following execution.

 

		2.3	Sublicensing. Licensee has the right to grant Sublicense Agreements under the Licensed
Subject Matter consistent with the terms of the Agreement, subject to the following:

 

		(a)	A Sublicense Agreement shall not exceed the scope and rights granted to Licensee hereunder. Sublicensee
must agree in writing to be bound by the applicable terms and conditions of this Agreement and shall indicate that Licensor is
a third party beneficiary of the Sublicense Agreement.

  

		(b)	Licensee shall deliver to Licensor a copy of each Sublicense Agreement granted by Licensee, Affiliate
or Sublicensee, and any modification or termination thereof, within thirty (30) days following the applicable execution, modification,
or termination of such Sublicense Agreement.

  

		(c)	Notwithstanding any such Sublicense Agreement, Licensee will remain primarily liable to Licensor
for all of the Licensee’s duties and obligations contained in the Agreement. Each Sublicense Agreement will contain a right
of termination by Licensee in the event that the Sublicensee breaches the payment or reporting obligations affecting Licensor or
any other terms and conditions of the Sublicense Agreement that would constitute a breach of the Agreement if such acts were performed
by Licensee.

  

		2.4	Diligent
                                         Commercialization. Licensee by itself or through its Affiliates and Sublicensees
                                         will use diligent and commercially reasonable efforts to commercialize Licensed Products
                                         and/or Licensed Processes in the Field of Use within the Territory. Without limiting
                                         the foregoing, Licensee will: (a) maintain a bona fide, funded, ongoing and active research,
                                         development, manufacturing, marketing, and sales program to diligently make, have made,
                                         use, sell, and have sold Licensed Products and/or Licensed Processes that are commercially
                                         available to the public as soon as commercially practicable, and (b) fulfill the milestone
                                         events specified in Section 2.4 of the PTLA by the deadlines indicated therein. If the
                                         obligations under this Section 2.4 are not fulfilled, Licensor may treat such failure
                                         as a breach in accordance with Section 7.3(b); provided, however, that if Licensee anticipates
                                         missing a milestone date and it has used and is using diligent and commercially reasonable
                                         efforts to commercialize Licensed Products and/or Licensed Processes in the Field of
                                         Use within the Territory, the parties shall negotiate in good faith reasonably appropriate
                                         extensions or other accommodations to the applicable milestone to enable Licensee to
                                         achieve such milestone, taking into consideration, Licensee’s active engagement
                                         in assessing drugability with respect to a Licensed Product and, after IND filing for
                                         a Licensed Product, Licensee’s ongoing engagement of pre-clinical and clinical
                                         development for Licensed Products which shall be evidenced by conducting at least one
                                         of the following activities in each year starting from the date of IND filing:

 

	{00258124-1}Licensee: Arno Therapeutics, Inc.	CONFIDENTIAL	Exclusive License (Non-Equity)
	Licensor: Ohio State Innovation Foundation	 	EXHIBIT A
	 	Page 9  of 25	 
	 		

    	 	 
INFORMATION MARKED BY [***] HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

	 

     

    

 

			(i) having expended at least five hundred thousand dollars ($500,000) for development of a Licensed
Product;

			(ii) having manufactured a Licensed Product suitable for clinical trials under an approved IND;

			(iii) having responded in full to all regulatory requests/issues relating to a Phase I, II or III
Clinical Trial of a Licensed Product;

			(iv) having prepared documents for NDA filing with respect to a Licensed Product;

			(v) having filed an NDA for a Licensed Product;

			(vi) following NDA filing, having actively pursued NDA approval for a Licensed Product;

			(vii) following NDA approval of Licensed Product, having launched or sold a Licensed Product in
the United States or another major market country.

 

		3.	Compensation. In consideration of rights granted to Licensee, Licensee will pay Licensor
all of the fees and royalties set forth in the PTLA and in accordance with these Terms and Conditions. Each payment will reference
the PTLA number and will be sent to Licensor’s payment and accounting contact in Section 18 of the PTLA.

  

		3.1	Royalties.
                                         Licensee will pay running royalties on
                                         Net Sales in each Contract Quarter on or before the Quarterly Payment Deadline
                                         for such Contract Quarter at the rate set
                                         forth in Section 3.1 of the PTLA. If royalties paid to Licensor do not reach the
                                         minimum royalty amounts stated in Section 3.1 of the PTLA in the stated period, then
                                         thirty (30) days after the end of such period, Licensee will pay Licensor an additional
                                         amount equal to the difference between the stated minimum royalty amount and the actual
                                         royalties paid to Licensor.

 

		4.	Reports and Plans.

  

		4.1	Reports. Utilizing the report forms in Appendix 1, Licensee will provide to Licensor’s
payment and reporting contact the following reports, including but not limited to: (a) the milestone report; (b) annual written
progress report on January 31; (c) commercial development report; and (d) quarterly payment and royalty report.

 

		5.	Payment, Records, and Audits.

  

		5.1	Payments. All amounts referred to in the PTLA are expressed in U.S. dollars without
deductions for taxes, assessments, fees, or charges of any kind. Each payment will reference the agreement number set forth at
the beginning of the PTLA. All payments to Licensor will be made in U.S. dollars by check or wire transfer (Licensee to pay all
wire or other transfer fees) payable to the payee identified in Section 18 and sent to the payment and reporting contact in Section
18. Licensee may not make any tax withholdings from payments to Licensor.  

  

		5.2	Sales Outside the U.S. If any currency conversion shall be required in connection
with the calculation of payments hereunder, such conversion shall be made using the rate used by Licensee for its financial reporting
purposes in accordance with U.S. Generally Accepted Accounting Principles (or foreign equivalent).

  

		5.3	Late Payments. Amounts that are not paid when due will accrue a late charge from
the due date until paid, at a rate equal to [***]% per month (or
the maximum allowed by law, if less).

  

	{00258124-1}Licensee: Arno Therapeutics, Inc.	CONFIDENTIAL	Exclusive License (Non-Equity)
	Licensor: Ohio State Innovation Foundation	 	EXHIBIT A
	 	Page 10  of 25	 
	 		

    	 	 
INFORMATION MARKED BY [***] HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

	 

     

    

 

		5.4	Records. For a period of six (6) years after the Contract Quarter to which the records
pertain, Licensee agrees that it and its Affiliates and Sublicensees each will keep complete and accurate records of their Sales,
Net Sales, royalty payment calculations, Milestone Fees, and Non-Royalty Sublicensing Consideration in sufficient detail to enable
such payments to be determined and audited.

  

		5.5	Auditing. Licensee and its Affiliates will permit Licensor or its representatives,
at Licensor’s expense, to periodically examine books, ledgers, and records during regular business hours, at Licensee’s
or its Affiliate’s place of business, on at least thirty (30) days advance notice, to the extent necessary to verify any
payment or report required under the Agreement. For each Sublicensee, Licensee shall obtain such audit rights for Licensor and
itself. If Licensee conducts an audit of the Sublicensee’s records, Licensee will furnish to Licensor a copy of the findings
from such audit. No more than one audit of Licensee, each Affiliate, and each Sublicensee shall be conducted under this Section 5.5
in any calendar year. If any amounts due Licensor have been underpaid, then Licensee shall immediately pay Licensor the amount
of such underpayment plus accrued interest due in accordance with Section 5.3. If the amount of underpayment is equal to or
greater than [***]% of the total amount due for the records so examined,
Licensee will pay the cost of such audit. Such audits may, at Licensor’s sole discretion, consist of a self-audit
conducted by Licensee at Licensee’s expense and certified in writing by an authorized officer of Licensee.

 

		6.	Patent Expenses and Prosecution.

  

		6.1	Patent Expenses. Licensee shall pay Licensor for all past patent expenses as set
forth in Section 3 of the PTLA. Licensee shall pay any additional past patent expenses as well as all future patent expenses incurred
by Licensor regarding the Patent Rights within forty-five (45) days after Licensee’s receipt of an invoice from Licensor.
Patent expense payment delinquencies (whether owed directly to Prosecution Counsel or to Licensor) will be considered a payment
default under Section 7.3(a).

 

		6.2	Direction of Prosecution. Licensor shall control the preparation, prosecution and
maintenance of the Patent Rights jointly with. Licensee using Prosecution Counsel mutually acceptable to Licensor for the preparation,
prosecution and maintenance of the Patent Rights. Licensor will provide or have provided copies of all material documents received
by Prosecution Counsel from patent offices regarding the Patent Rights and the material documents prepared by Prosecution Counsel
for submission to patent offices be provided to Licensee for review and comment prior to filing to the extent practicable under
the circumstances.

  

		6.3	Ownership. All patent applications and patents will be in the name of Licensor (and
any co-owner identified in Section 1 of the PTLA) and owned by Licensor (and such co-owner, if any).

  

		6.4	Foreign Filings. In addition to the U.S., the Patent Rights shall, subject to applicable
bar dates, be pursued in such foreign countries as Licensee so designates in writing to Licensor in sufficient time to reasonably
enable the preparation of such additional filings, and in those foreign countries in which Licensor has filed applications prior
to the Effective Date. If Licensee does not choose to pursue patent rights in a particular foreign country and Licensor chooses
to do so, Licensee shall so notify Licensor and thereafter said patent application or patent shall no longer be included in the
Patent Rights and Licensee shall have no further rights thereto. Licensor shall have the right to make alternative arrangements
with Licensee for upfront payment of foreign patent expenses.

  

	{00258124-1}Licensee: Arno Therapeutics, Inc.	CONFIDENTIAL	Exclusive License (Non-Equity)
	Licensor: Ohio State Innovation Foundation	 	EXHIBIT A
	 	Page 11  of 25	 
	 		

    	 	 
INFORMATION MARKED BY [***] HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

	 

     

    

 

		6.5	Withdrawal from Paying Patent Costs. If at any time Licensee wishes to cease paying
for any costs for a particular Patent Right or for patent prosecution in a particular jurisdiction, Licensee must give Licensor
at least ninety (90) days prior written notice and Licensee will continue to be obligated to pay for the patent costs which reasonably
accrue during said notice period. Thereafter, said patent application or patent shall no longer be included in the Patent Rights
and Licensee shall have no further rights thereto.

  

		7.	Term and Termination.

  

		7.1	Term. Unless earlier terminated as provided herein, the term of the Agreement will
commence on the Effective Date and continue until the last date of expiration or termination of the Patent Rights or, if Technology
Rights are licensed and no Patent Rights are applicable, for a term of twenty (20) years.

  

		7.2	Termination by Licensee. Licensee, at its option, may terminate the Agreement by
providing Licensor written notice of termination and such termination will become effective ninety (90) days after receipt of such
notice by Licensor; except that if Licensee provides Licensor written notice of termination before the first anniversary of the
Effective Date, such termination will become effective thirty (30) days after receipt of such notice by Licensor.

 

		7.3	Termination by Licensor. Licensor, at its option, may immediately terminate the Agreement,
or any part of Licensed Subject Matter, or any part of Field of Use, or any part of Territory, or the exclusive nature of the license
grant, upon delivery of written notice to Licensee of Licensor’s decision to terminate, if any of the following occur:

  

		(a)	Licensee becomes in arrears in any payments due under the Agreement, and Licensee fails to make
the required payment within fifteen (15)) days after delivery of written notice from Licensor; or

  

		(b)	Licensee is in breach of any non-payment provision of the Agreement, and does not cure such breach
within forty (40) days after delivery of written notice from Licensor; or

  

		(c)	Licensee or its Affiliate or Sublicensee initiates any proceeding or action to challenge the validity,
enforceability, or scope of one or more of the Patent Rights, or assist a third party in pursuing such a proceeding or action.

  

		7.4	Other Conditions of Termination. The Agreement will terminate:

 

		(a)	Immediately, without the necessity of any action being taken by Licensor or Licensee, (i) if Licensee
files a bankruptcy action or becomes bankrupt or insolvent, or (ii) Licensee’s Board of Directors elects to liquidate its
assets or dissolve its business, or (iii) Licensee ceases its business operations, or (iv) Licensee makes an assignment for the
benefit of creditors, or (v) if the business or assets of Licensee are otherwise placed in the hands of a receiver, assignee or
trustee, whether by voluntary act of Licensee or otherwise; or

  

	{00258124-1}Licensee: Arno Therapeutics, Inc.	CONFIDENTIAL	Exclusive License (Non-Equity)
	Licensor: Ohio State Innovation Foundation	 	EXHIBIT A
	 	Page 12  of 25	 
	 		

    	 	 
INFORMATION MARKED BY [***] HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

	 

     

    

 

		(b)	At any time by mutual written agreement between Licensee and Licensor.

  

		7.5	Effect of Termination. If the Agreement is terminated for any reason:

 

		(a)	All Sublicenses that are granted by Licensee pursuant to this Agreement, where the Sublicensee
is in compliance with its Sublicense Agreement as of the date of such termination, will remain in effect and will be assigned to
Licensor, except that Licensor will not be bound to perform any duties or obligations set forth in any Sublicenses that extend
beyond the duties and obligations of Licensor set forth in this Agreement; and

  

		(b)	Licensee shall cease making, having made, distributing, having distributed, using, selling, offering
to sell, leasing, loaning and importing any Licensed Products and performing Licensed Processes by the effective date of termination;
and

 

		(c)	Licensee shall tender payment of all accrued royalties and other payments due to Licensor as of
the effective date of termination within thirty (30) business days after the effective date of termination; and

 

		(d)	Licensee shall tender payment of all unreimbursed patent expenses, including those scheduled in
Sections 3 and 20 of the PTLA and those expenses payable under Section 6 of these Terms and Conditions within thirty (30) business
days after the effective date of termination; and

 

		(e)	Nothing in the Agreement will be construed to release either Party from any obligation that matured
prior to the effective date of termination; and

  

		(f)	The provisions of Sections 8 (Confidentiality),
9.4 (Cooperation),
11 (Representations
and Disclaimers), 12 (Limit of Liability), 13 (Indemnification),
14 (Insurance),
17 (Use
of Name), 18 (Notices), and 19 (General
Provisions) will survive any termination or expiration of the Agreement. In addition, the provisions of Sections 3 (Compensation),
4 (Reports and Plans), 5 (Payment, Records and Audits), and 6.1 (Patent Expenses) shall survive with respect to all activities
and payment obligations accruing prior to the termination or expiration of the Agreement.

  

		8.	Confidentiality. Recipient will use best efforts to safeguard the confidentiality
of the Confidential Information and will not provide any Confidential Information to third parties without Discloser’s prior
written consent. Recipient will permit its employees to have access to the Confidential Information only on a need-to-know basis,
and then only on the basis of a clear understanding by these individuals of the obligations hereunder. Recipient is under no obligation
for any Confidential Information which: (a) it can demonstrate by written records was previously known to it; (b) is now, or becomes
in the future, public knowledge other than through its own acts or omissions; (c) it independently develops by those not having
access to the Confidential Information and which can be proven through verifiable records; (d) it lawfully obtains from a source
independent of the Discloser; or (e) is required by applicable law to be disclosed. Notwithstanding the foregoing, the existence
of the Agreement shall not be considered Confidential Information. Subject to the exclusions listed above, the Parties’
confidentiality obligations under the Agreement will survive termination of the Agreement and will continue for a period of three
(3) years thereafter.

 

 

	{00258124-1}Licensee: Arno Therapeutics, Inc.	CONFIDENTIAL	Exclusive License (Non-Equity)
	Licensor: Ohio State Innovation Foundation	 	EXHIBIT A
	 	Page 13  of 25	 
	 		

    	 	 
INFORMATION MARKED BY [***] HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

	 

     

    

 

		9.	Infringement and Litigation.

  

		9.1	Notification. If either Licensor’s designated office for technology commercialization
or Licensee becomes aware of any infringement or potential infringement of Patent Rights, each Party shall promptly notify the
other of such in writing.

  

		9.2	Licensee’s Enforcement Rights. Licensee shall have the first right, but not
the obligation, to enforce the Patent Rights against any infringement by a third party in the Field in the Territory, within a
period of six (6) months from notice of such infringement.  Licensee shall be responsible for payment of [***]fees
and expenses associated with such enforcement incurred by Licensee and incurred by Licensor in providing cooperation
or joining as a party as provided in Section 9.4.  [***] percent
([***]%) of any monetary recovery for actual damages or punitive
damages, in excess of Licensee’s documented, third-party expenses in enforcing the Patent Rights and amounts actually reimbursed
by Licensee to Licensor under this Section 9.2, shall be shared with Licensor.

  

		9.3	Licensor’s Enforcement Rights. If Licensee does not file suit within six (6)
months after a written request by Licensor to initiate an infringement action, or earlier if Licensee provides written notice to
Licensor that Licensee will not initiate infringement action, then Licensor shall have the right, at its sole discretion, to bring
suit to enforce any Patent Right licensed hereunder against the infringing activities, with Licensor retaining all recoveries from
such enforcement.

  

		9.4	Cooperation between Licensor and Licensee. In any infringement suit or dispute, the
Parties agree to cooperate fully with each other in a reasonable manner. If it is necessary to name Licensor as a party in such
action, then Licensee must first obtain Licensor’s prior written permission, which permission shall not be unreasonably withheld,
provided that Licensor shall have reasonable prior input on choice of counsel on any matter where such counsel represents Licensor.

  

		10.	Export Compliance. Licensee and Licensor shall observe all applicable United States
and foreign laws and regulations with respect to the research, development, manufacture, marketing and transfer of Licensed Products
and related technical data, including, without limitation, the International Traffic in Arms Regulations (ITAR) and the Export
Administration Regulation. Licensee hereby represents and covenants that Licensee: (a) is neither a national of, nor controlled
by a national of, any country to which the United States prohibits the export or re-export of goods, services, or technology; (b)
is not a person specifically designated as ineligible to export from the United States or deal in U.S.-origin goods, services,
or technologies; (c) shall not export or re-export, directly or indirectly, any goods, services, or technology to any country or
person (including juridical persons) to which the United States prohibits the export of goods, technology or services; and (d)
in the event that a United States government license or authorization is required for an export or re-export of goods, services,
or technology (including technical information acquired from Licensor under this Agreement and/or any products created by using
such technical information or any part thereof), shall obtain any necessary United States government license or other authorization
prior to undertaking the export or re-export. Licensee and Licensor shall include a provision in its agreements, substantially
similar to this Section 10, with its Sublicensees, third party persons or entities who receive or purchase a Licensed Product,
requiring that these parties comply with all then-current applicable export laws and regulations and other applicable laws and
regulations.

 

 

	{00258124-1}Licensee: Arno Therapeutics, Inc.	CONFIDENTIAL	Exclusive License (Non-Equity)
	Licensor: Ohio State Innovation Foundation	 	EXHIBIT A
	 	Page 14  of 25	 
	 		

    	 	 
INFORMATION MARKED BY [***] HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

	 

     

    

 

		11.	Representations and Disclaimers.

  

		11.1	Licensor Representations. Except for the rights, if any, of the Government, Licensor
represents and warrants to Licensee that to the knowledge of Licensor’s designated office for technology commercialization:
(a) Licensor is the owner or agent of the entire right, title, and interest in and to Patent Rights (other than the right, title
and interest of any joint owner identified in Section 1 of the PTLA) and has taken all reasonable steps necessary to perfect its
ownership in and to Patent Rights;); (b) Licensor has the right to grant the license and sublicense hereunder;, (c) Licensor has
not knowingly granted and will not knowingly grant licenses or other rights under the Patent Rights that are in conflict with the
terms and conditions in the Agreement, and (d) Licensor has disclosed any applicable Government Rights in the Patent Rights to
Licensee.

  

		11.2	Government Rights. Licensee understands that Licensed Subject Matter may have been
developed under a funding agreement with Government and, if so, that Government may have certain rights relative thereto. The Agreement
is made subject to the Government’s rights under any such agreement and under any applicable Government law or regulation.
To the extent that there is a conflict between any such agreement, such applicable law or regulation and the Agreement, the terms
of such Government agreement, and applicable law or regulation, shall prevail.

  

		11.3	Licensor Disclaimers. EXCEPT AS SPECIFICALLY SET FORTH IN SECTION 11.1, LICENSEE
UNDERSTANDS AND AGREES THAT LICENSOR MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING, WITHOUT
LIMITATION, AS TO THE LICENSED PRODUCTS OR LICENSED PROCESSES OR AS TO THE OPERABILITY OR FITNESS FOR ANY USE OR PARTICULAR PURPOSE,
MERCHANTABILITY, SAFETY, EFFICACY, APPROVABILITY BY REGULATORY AUTHORITIES, TIME AND COST OF DEVELOPMENT, PATENTABILITY, NONINFRINGEMENT,
AND/OR BREADTH OF PATENT RIGHTS. LICENSOR MAKES NO REPRESENTATION AS TO WHETHER ANY CLAIM OR PATENT WITHIN PATENT RIGHTS IS VALID,
OR AS TO WHETHER THERE ARE ANY PATENTS NOW HELD, OR WHICH WILL BE HELD, BY OTHERS OR BY LICENSOR THAT MIGHT BE REQUIRED FOR USE
OF PATENT RIGHTS IN THE FIELD OF USE. NOTHING IN THE AGREEMENT WILL BE CONSTRUED AS CONFERRING BY IMPLICATION, ESTOPPEL OR OTHERWISE
ANY LICENSE OR RIGHTS TO ANY PATENTS OR TECHNOLOGY OF LICENSOR OTHER THAN THE PATENT RIGHTS, WHETHER SUCH PATENTS ARE DOMINANT
OR SUBORDINATE TO THE PATENT RIGHTS, OR THE TECHNOLOGY RIGHTS SPECIFICALLY DESCRIBED HEREIN.

  

		11.4	Licensee Representation. By execution of the Agreement, Licensee represents, acknowledges,
covenants and agrees that: (a) Licensee has not been induced in any way by Licensor or its employees to enter into the Agreement;
(b) Licensee has been given an opportunity to conduct sufficient due diligence with respect to all items and issues pertaining
to this Section 11 (Representations and Disclaimers) and all other
matters pertaining to the Agreement; (c) Licensee has adequate knowledge and expertise, or has utilized knowledgeable and expert
consultants, to adequately conduct the due diligence; and (d) Licensee accepts all risks inherent herein. Licensee represents that
it is a duly organized, validly existing entity of the form indicated in Section 1 of the PTLA, and is in good standing under the
laws of its jurisdiction of organization as indicated in Section 1 of the PTLA, and has all necessary corporate or other appropriate
power and authority to execute, deliver and perform its obligations hereunder.

 

 

	{00258124-1}Licensee: Arno Therapeutics, Inc.	CONFIDENTIAL	Exclusive License (Non-Equity)
	Licensor: Ohio State Innovation Foundation	 	EXHIBIT A
	 	Page 15  of 25	 
	 		

    	 	 
INFORMATION MARKED BY [***] HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

	 

     

    

 

		12.	Limit of Liability. IN NO EVENT SHALL LICENSOR, OSU, OR THEIR INVENTORS, OFFICERS,
EMPLOYEES, STUDENTS, TRUSTEES, AGENTS OR AFFILIATED ENTERPRISES, BE LIABLE FOR ANY INDIRECT, SPECIAL, CONSEQUENTIAL, INCIDENTAL,
EXEMPLARY, OR PUNITIVE DAMAGES (INCLUDING, WITHOUT LIMITATION, DAMAGES FOR LOSS OF PROFITS OR REVENUE) ARISING OUT OF OR IN CONNECTION
WITH THE AGREEMENT OR ITS SUBJECT MATTER, REGARDLESS OF WHETHER ANY SUCH PARTY KNOWS OR SHOULD KNOW OF THE POSSIBILITY OF SUCH
DAMAGES. OTHER THAN FOR CLAIMS AGAINST LICENSEE FOR INDEMNIFICATION (SECTION 13), CLAIMS AGAINST LICENSOR FOR LICENSOR REPRESENTATIONS
(11.1), OR FOR CLAIMS AGAINST LICENSOR FOR MISUSE OR MISAPPROPRIATION OR INFRINGEMENT OF LICENSEE’S INTELLECTUAL PROPERTY
RIGHTS, LICENSEE WILL NOT BE LIABLE TO LICENSOR FOR ANY INDIRECT, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES (INCLUDING, WITHOUT
LIMITATION, DAMAGES FOR LOSS OF PROFITS OR REVENUE) ARISING OUT OF OR IN CONNECTION WITH THE AGREEMENT OR ITS SUBJECT MATTER, REGARDLESS
OF WHETHER LICENSEE KNOWS OR SHOULD HAVE KNOWN OF THE POSSIBILITY OF SUCH DAMAGES.

  

		13.	Indemnification Obligation. Licensee agrees to hold harmless, defend and indemnify
Licensor, OSU, their affiliates, and their officers, employees, students, inventors, trustees, agents, and consultants (“Indemnified
Parties”) from and against any liabilities, damages, causes of action, suits, judgments, liens, penalties, fines, losses,
costs and expenses (including, without limitation, reasonable attorneys’ fees and other expenses of litigation) (collectively
“Liabilities”) resulting from claims or demands brought by third parties against an Indemnified Party on account of
any injury or death of persons, damage to property, or any other damage or loss arising out of or in connection with the Agreement
or the exercise or practice by or under authority of Licensee, its Affiliates or their Sublicensees, or third party person or entity
who purchases a Licensed Product, of the rights granted hereunder. Licensee shall have no responsibility or obligation under this
section for any Liabilities to the extent caused by the gross negligence or willful misconduct by Licensor.

  

		14.	Insurance Requirements. Prior to any Licensed Product or Licensed Process being used
or Sold (including for the purpose of obtaining regulatory approval) by an Affiliate or by a Sublicensee, and for a period of five
years after the Agreement expires or is terminated, Licensee shall, at its sole cost and expense, procure and maintain commercial
general liability insurance in commercially reasonable and appropriate amounts for the Licensed Product or Licensed Process being
used or Sold. Licensee shall use commercially reasonable efforts to have Licensor, its affiliates, its officers, and employees
named as additional insureds. Such commercial general liability insurance shall provide, without limitation: (a) product liability
coverage; (b) broad form contractual liability coverage for Licensee’s indemnification under the Agreement; and (c) coverage
for litigation costs. Upon request by Licensor, Licensee shall provide Licensor with written evidence of such insurance. Additionally,
Licensee shall provide Licensor with advance written notice of at least sixty (60) days prior to Licensee cancelling, not renewing,
or materially changing such insurance.

  

		15.	Assignment. This Agreement is not assignable or otherwise transferable (including
by operation of law, merger or other business combination) by Licensee without the prior written consent of Licensor, which consent
will not be unreasonably withheld. For any permitted assignment or transfer to be effective, (a) Licensee must be in good standing
under this Agreement, and (b) the assignee must assume in writing (a copy of which shall be promptly provided to Licensor) all
of Licensee’s interests, rights, duties and obligations under the Agreement and agree to comply with all terms and conditions
of the Agreement as if assignee were an original Party to the Agreement.

 

 

	{00258124-1}Licensee: Arno Therapeutics, Inc.	CONFIDENTIAL	Exclusive License (Non-Equity)
	Licensor: Ohio State Innovation Foundation	 	EXHIBIT A
	 	Page 16  of 25	 
	 		

    	 	 
INFORMATION MARKED BY [***] HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

	 

     

    

 

		16.	Patent Markings. Licensee agrees that all Licensed Products Sold by Licensee, Affiliates,
and Sublicensees will be marked in accordance with each country’s patent marking laws, including Title 35, U.S. Code,
in the United States.

 

		17.	Use of Name. Licensee will not use the name, trademarks or other marks of Licensor
or OSU without the advance written consent of Licensor and OSU. Licensor and OSU may use Licensee’s name and logo
for annual reports, brochures, website and internal reports without prior consent.

 

		18.	Notices. Any notice or other communication of the Parties required or permitted to
be given or made under the Agreement will be in writing and will be deemed effective when sent in a manner that provides confirmation
or acknowledgement of delivery and received at the address set forth in Section 18 of the PTLA (or as changed by written notice
pursuant to this Section 18). Notices required under the Agreement
may be delivered via E-mail provided such notice is confirmed in writing as indicated. Late payment notices are sufficiently delivered
via E-mail only.

 

		19.	General Provisions.

 

		19.1	Binding Effect. The Agreement is binding upon and inures to the benefit of the Parties
hereto, their respective executors, administrators, heirs, permitted assigns, and permitted successors in interest.

 

		19.2	Construction of Agreement. Both Parties agree that any ambiguity in the Agreement
shall not be construed more favorably toward one Party than the other Party, regardless of which Party primarily drafted the Agreement.

 

		19.3	Counterparts and Signatures. The Agreement may be executed in multiple counterparts,
each of which shall be deemed an original, but all of which taken together shall constitute one and the same instrument. A Party
may evidence its execution and delivery of the Agreement by transmission of a signed copy of the Agreement via facsimile or email.

 

		19.4	Compliance with Laws. Licensee will comply with all applicable federal, state and
local laws and regulations.

 

		19.5	Governing Law; Jurisdiction. The Agreement will be construed and enforced in accordance
with laws of the State of Ohio, without regard to choice of law and conflicts of law principles. The Parties agree that any claim
or cause of action regarding this Agreement shall be brought in a court of competent jurisdiction in Ohio and this is the parties’
sole and exclusive process for seeking a remedy for any and all claims and causes of action regarding this Agreement.

 

		19.6	Modification. Any modification of the Agreement will be effective only if it is in
writing and signed by duly authorized representatives of both Parties.

 

 

	{00258124-1}Licensee: Arno Therapeutics, Inc.	CONFIDENTIAL	Exclusive License (Non-Equity)
	Licensor: Ohio State Innovation Foundation	 	EXHIBIT A
	 	Page 17  of 25	 
	 		

    	 	 
INFORMATION MARKED BY [***] HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

	 

     

    

 

		19.7	Severability. If any provision hereof is held to be invalid, illegal or unenforceable
in any jurisdiction, the Parties hereto shall negotiate in good faith a valid, legal and enforceable substitute provision that
most nearly reflects the original intent of the Parties, and all other provisions hereof shall remain in full force and effect
in such jurisdiction and shall be construed in order to carry out the intentions of the Parties hereto as nearly as may be possible.
Such invalidity, illegality or unenforceability shall not affect the validity, legality or enforceability of such other provisions
in any other jurisdiction, so long as the essential essence of the Agreement remains enforceable.

 

		19.8	Third Party Beneficiaries. Nothing in the Agreement, express or implied, is intended
to confer any benefits, rights or remedies on any entity, other than the Parties, OSU, and their permitted successors and assigns.
However, if there is a joint owner of any Patent Rights identified in Section 1 of the PTLA (other than Licensee), then Licensee
hereby agrees that the following provisions of these Terms and Conditions extend to the benefit of the co-owner identified therein
(excluding the Licensee to the extent it is a co-owner) as if such co-owner was identified in each reference to the Licensor: the
retained rights under Section 2.1(d); Section 11.3 (Licensor Disclaimers); Section 12 (Limit of Liability); Section 13 (Indemnification);
Section 14.1 (Insurance Requirements); Section 17 (Use of Name); and Section 19.10 (Sovereign Immunity, if applicable).

 

		19.9	Waiver. Neither Party will be deemed to have waived any of its rights under the Agreement
unless the waiver is in writing and signed by such Party. No delay or omission of a Party in exercising or enforcing a right or
remedy under the Agreement shall operate as a waiver thereof.

 

		19.10	Sovereign Immunity. Nothing in the Agreement
shall be deemed or treated as any waiver of OSU’s sovereign immunity.

 

		19.11	Cross Default.  In the event that
Licensee is a party to any other agreement with Licensor, a default by Licensee of this or any other agreement shall be deemed
a default under all other agreements with Licensor and OSU.

 

		19.12	Entire
Agreement. The agreement constitutes the entire
agreement between the parties regarding the subject matter hereof, and supersedes all prior written or verbal agreements, representations
and understandings relative to such matters.

 

 

	{00258124-1}Licensee: Arno Therapeutics, Inc.	CONFIDENTIAL	Exclusive License (Non-Equity)
	Licensor: Ohio State Innovation Foundation	 	EXHIBIT A
	 	Page 18  of 25	 
	 		

    	 	 
INFORMATION MARKED BY [***] HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

	 

     

    

 

Appendix
1A

 

MILESTONE
REPORT

 

 

	Licensee: ______________________________	Agreement No: ___________________________
	Inventor: ______________________________	Licensor Tech ID No: _______________________
	Period Covered From: ____________________	Through: ________________________________
	Prepared By: ___________________________	Date: ___________________________________
	Approved By: __________________________	Date: ___________________________________

  

	Milestone Events	
         

        Milestone
        Fees

        Due by the Quarterly

Payment Deadline
        for the

Contract Quarter in which the

milestone events are achieved

         
	Deadlines	Date Completed
	1.                                 	$                                	                               	 
	2.                                	$                                	                               	 
	3.                                	$                                	                               	 
	4.                                	$                                	                               	 
	5.                                	$                                	                               	 

 

 

I certify
that this report is accurate and complete: ________________________________________

 

Description of Milestone Activities:

 

		1.	

 

		2.	

 

		3.	

 

Please return one copy of
this form along with your report to the following address:

 

Ohio State Innovation Foundation

Attn: Compliance

 

Technology Commercialization
Office

1524 North High Street

 

Columbus, OH 43201

 

  

If you have questions, please
call (614) 292-1315, send a fax to (614) 292-8907 (Attn: Compliance), or send an email to tcocompliance@osu.edu. Thank you for
your prompt attention.

 

 

	{00258124-1}Licensee: Arno Therapeutics, Inc.	CONFIDENTIAL	Exclusive License (Non-Equity)
	Licensor: Ohio State Innovation Foundation	 	EXHIBIT A
	 	Page 19  of 25	 
	 		

    	 	 
INFORMATION MARKED BY [***] HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

	 

     

    

 

Appendix
1B

 

ANNUAL
REPORT

 

Page 1

  

	 	 
	Licensee: ______________________________	Agreement No: ___________________________
	Inventor: ______________________________	Licensor Tech ID No: _______________________
	Period Covered From: ____________________	Through: ________________________________
	Prepared By: ___________________________	Date: ___________________________________
	Approved By: __________________________	Date: ___________________________________

  

 

	
        ANNUAL
        REPORT FOR THE PERIOD

         

         

         

 

An annual report is due on ______________________
covering the status of all patent prosecution, commercial development, and licensing activities relating to the invention(s) covered
by the above Agreement. (Please refer to the Agreement paragraph ___________).

 

	 
	
        Government regulations (Bayh-Dole)
        require reporting of any request to waive standard U.S. manufacturing requirements. Have you requested such a waiver from a government
        agency?

         

         ̈  Yes
   ̈  No
 

        If yes, please attach additional
        information and give the agency name, date requested, and/or date granted.

         

	
        Submitted By: ____________________________

        Title: ___________________________________

        Email: ___________________________________

         
	
        Date: ____________________

        Phone: ___________________

 

 

Please return one copy of this form along
with your report to the following address:

 

Ohio State Innovation Foundation

Attn: Compliance

 

Technology Commercialization Office

1524 North High Street

 

Columbus, OH 43201

 

 

If you have questions, please call (614)
292-1315, send a fax to (614) 292-8907 (Attn: Compliance), or send an email to tcocompliance @osu.edu. Thank you for your prompt
attention.

 

 

	{00258124-1}Licensee: Arno Therapeutics, Inc.	CONFIDENTIAL	Exclusive License (Non-Equity)
	Licensor: Ohio State Innovation Foundation	 	EXHIBIT A
	 	Page 20  of 25	 
	 		

    	 	 
INFORMATION MARKED BY [***] HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

	 

     

    

 

Appendix
1B

ANNUAL
REPORT

Page 2

 

For the
Period:_________________

 

	Patent Activity

 

 

	License/Sublicense Activity

 

	Description of Commercial Development (see attached form)

 

	Management 
	Title	Name	Since (Date)
	CEO	 	 
	COO	 	 
	CFO	 	 
	CTO/CMO	 	 

 

Please return one copy of this form along
with your report to the following address:

 

Ohio State Innovation Foundation

Attn: Compliance

 

Technology Commercialization Office

1524 North High Street

 

Columbus, OH 43201

 

If you have questions, please call (614)
292-1315, send a fax to (614) 292-8907 (Attn: Compliance), or send an email to tcocompliance @osu.edu. Thank you for your prompt
attention.

 

 

	{00258124-1}Licensee: Arno Therapeutics, Inc.	CONFIDENTIAL	Exclusive License (Non-Equity)
	Licensor: Ohio State Innovation Foundation	 	EXHIBIT A
	 	Page 21  of 25	 
	 		

    	 	 
INFORMATION MARKED BY [***] HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

	 

     

    

 

Appendix
1B

ANNUAL
REPORT

 

Page 3

 

For the
Period:_________________

 

	Description of any Key Other Events

 

 

 

 

 

 

 

Please return one copy of this form along
with your report to the following address:

 

Ohio State Innovation Foundation

Attn: Compliance

 

Technology Commercialization Office

1524 North High Street

 

Columbus, OH 43201

 

If you have questions, please call (614)
292-1315, send a fax to (614) 292-8907 (Attn: Compliance), or send an email to tcocompliance @osu.edu. Thank you for your prompt
attention.

  

	{00258124-1}Licensee: Arno Therapeutics, Inc.	CONFIDENTIAL	Exclusive License (Non-Equity)
	Licensor: Ohio State Innovation Foundation	 	EXHIBIT A
	 	Page 22  of 25	 
	 		

    	 	 
INFORMATION MARKED BY [***] HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

	 

     

    

 

Appendix
1B

ANNUAL
REPORT

Page 4

For the
Period:_________________

COMMERCIAL
DEVELOPMENT REPORT

Please select the type of product in development,
check its current state of development, and complete the fields for the other information in the box. If you have additional information,
please attach it to the end of this form.

 

 

Therapeutic
Products Date ? Discovery _________________ ? Pre-Clinical _________________ ? Phase I Clinical Trials _________________ ? Phase
II Clinical Trials _________________ ? Phase III Clinical Trials _________________ ? NDA Submitted _________________ ? Selling
Licensed Products _________________ ? Other: _________________ _________________ Drug in Development (brand name, if applicable):
Hardware/Engineering Products Date ? Research _________________ ? Functioning Prototype _________________ ? Beta Testing _________________
? Pilot Manufacturing Run _________________ ? Safety Tested _________________ _________________ ? Selling Licensed Products _________________
? Other: _________________ _________________ Product in Development (brand name, if applicable): __________________________________________________
Market Addressed: _________________________________ Software Date ? In Development _________________ ? Alpha Testing _________________
? Beta Testing _________________ _________________ ? Selling Licensed Products _________________ ? Other: _________________ _________________
Tool in Development (brand name, if applicable): _________________________________________ Application: _____________________________________Copyright/Trademarked
Products Date ? Functioning Prototype _________________ ? Alpha Testing _________________ ? Beta Testing _________________ _________________
? Selling Licensed Products _________________ ? Other: _________________ _________________ Product in Development (brand name,
if applicable): __________________________________________ Market Addressed: _______________________________ Plant Products Date
? Discovery _________________ ? Gvt. Approval Applied For _________________ ? Gvt. Approval Received _________________ _________________
? Selling Licensed Products _________________ ? Other: _________________ _________________ Product in Development (brand name,
if applicable): __________________________________________________ Field of Product: _________________________________Medical
Devices/Diagnostics Date ? Research _________________ ? Pre-Clinical _________________ ? 510(k)/CE Mark Submitted _________________
? PMA _________________ _________________ ? Selling Licensed Products _________________ ? Other: _________________ _________________
Device/Diagnostic in Development (brand name, if applicable): __________________________________________________ Medical Field:
_____________________________________ Please return one copy of this form along with your report to the following address:
Ohio State Innovation Foundation
Attn: Compliance
Technology Commercialization Office
1524 North High Street
Columbus, OH 43201If you have questions, please call (614) 292-1315, send a fax to (614) 292-8907 (Attn: Compliance), or send an email to tcocompliance@osu.edu. Thank you for your prompt attention.

 

	{00258124-1}Licensee: Arno Therapeutics, Inc.	CONFIDENTIAL	Exclusive License (Non-Equity)
	Licensor: Ohio State Innovation Foundation	 	EXHIBIT A
	 	Page 23  of 25	 
	 		

    	 	 
INFORMATION MARKED BY [***] HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

	 

     

    

 

Appendix 1C

 

ROYALTY
REPORT

Page 1

	 	 
	Licensee: ______________________________	Agreement No: ___________________________
	Inventor: ______________________________	Licensor Tech ID No: _______________________
	Period Covered From: ____________________	Through: ________________________________
	Prepared By: ___________________________	Date: ___________________________________
	Approved By: __________________________	Date: ___________________________________

 

If license
covers several major product lines, please prepare a separate report for each line. Then combine all product lines into a summary
report.

 

Report
Type:

 ̈    Single
Product Line Report: ___________________________________________________________________

 ̈    Multiproduct Summary Report: ________________________________________________________________

Page 1 of ____ pages

 

	Product Line Details:	Line: _______________________	Trade Name: _______________________
	 	 	Pages: ______________________

  

	Report Currency:	 ̈   U.S.
Dollars	 ̈   Other:
__________________________

	 	Country	Gross Consideration	Allowances	Net Sales1	Royalty Rate	Royalty Amount	Royalty Paid Last Year	Next Year Royalty Forecast2
	1. Total Q1	                         	                         	                         	                         	                         	                         	                         	                         
	                         	                         	                         	                         	                         	                         	                         	                         
	                         	                         	                         	                         	                         	                         	                         	                         
	2. Total Q2	                         	                         	                         	                         	                         	                         	                         	                         
	                         	                         	                         	                         	                         	                         	                         	                         
	                         	                         	                         	                         	                         	                         	                         	                         
	3. Total Q3	                         	                         	                         	                         	                         	                         	                         	                         
	                         	                         	                         	                         	                         	                         	                         	                         
	                         	                         	                         	                         	                         	                         	                         	                         
	4. Total Q4	                         	                         	                         	                         	                         	                         	                         	                         
	 	 	 	 	 	 	 	 
	                         	                         	                         	                         	                         	                         	                         	                         
	5. Total FY _	                         	                         	                         	                         	                         	                         	                         	                         
	6. Minimum Annual Royalty	                         	                         	                         	                         	                         	                         	                         	                         
	7. Annual Royalty3 for FY__	                         	                         	                         	                         	                         	                         	                         	                         
	8. Amount Paid-to-Date4 	                         	                         	                         	                         	                         	                         	                         	                         
	9. Amount Payable5 	                         	                         	                         	                         	                         	                         	                         	                         

 

	Total Royalty: ________________	Conversion Rate: _________	Royalty in U.S. Dollars: _______________

 

1 means the Gross
Consideration paid to, received by, or given to Licensee, Affiliates, and Sublicensees from the Sale of Licensed Products and Licensed
Processes, less the following items directly attributable to the Sale of such Licensed Products that are specifically identified
on the invoice for such Sale and borne by the Licensee, Affiliates, or Sublicensees as the seller: (a) discounts and rebates actually
granted; (b) sales, value added, use and other taxes and government charges actually paid, excluding income taxes; (c) import and
export duties actually paid; (d) freight, transport, packing and transit insurance charges actually paid or allowed; and (e) other
amounts actually refunded, allowed or credited due to rejections or returns, but not exceeding the original invoiced amount.

 

2 The royalty forecast
is non-binding and is for OSIF’s internal planning purposes only

 

3 (greater of line
5 or 6)

 

4 (lines 1+2+3)

 

5 (line 7 - line 8)

 

	{00258124-1}Licensee: Arno Therapeutics, Inc.	CONFIDENTIAL	Exclusive License (Non-Equity)
	Licensor: Ohio State Innovation Foundation	 	EXHIBIT A
	 	Page 24  of 25	 
	 		

    	 	 
INFORMATION MARKED BY [***] HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

	 

     

    

 

Appendix
1C

 

ROYALTY
REPORT

 

Page 2

 

 

Any other consideration due Licensor
during this Royalty Period:

 

	Milestones: ________________________	 
	 	 
	Minimum Royalties: _________________	Sublicense Payments: __________________

 

 

	
         

         

        On a separate page, please indicate
        the reason for returns or adjustments if significant. Also note any unusual occurrences that affect royalty

        amounts during this
        period. To assist OSIF’s forecasting, please comment on any significant expected trends in sales volume.

          

         

 

 

I certify
that this report is accurate and complete: ________________________________________

 

 

Please return one copy of this form along
with your report to the following address:

 

Ohio State Innovation Foundation

Attn: Compliance

 

Technology Commercialization Office

1524 North High Street

 

Columbus, OH 43201

 

If you have questions, please call (614)
292-1315, send a fax to (614) 292-8907 (Attn: Compliance), or send an email to tcocompliance @osu.edu. Thank you for your prompt
attention.

 

	{00258124-1}Licensee: Arno Therapeutics, Inc.	CONFIDENTIAL	Exclusive License (Non-Equity)
	Licensor: Ohio State Innovation Foundation	 	EXHIBIT A
	 	Page 25  of 25	 
	 		

    	 	 
INFORMATION MARKED BY [***] HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.Exhibit 10.47

November 10, 2015

Findex.com, Inc.

1313 South Killian Drive

Lake Park, FL 33403

Gentlemen:

J.N.B., LLC., located at the address set forth below (“Advisor”), is pleased to be retained on the terms and conditions set forth in this letter of engagement (“Engagement Letter”) as a consultant to your company, Findex.com, Inc., a Nevada corporation (the “Company”), to assist in a variety of areas relating to the strategic and business developmental growth of the Company in the oil & gas markets (the “Engagement”).

1.               Scope of Services.

For the Term of Engagement (as hereinafter defined), and with your general knowledge and consent, we agree to provide to the Company a range of business relationship-based consultative and related services which may, but which will not necessarily, include the following: (i) identifying and introducing prospective new customers and licensees for the Company’s products within and throughout the global oil and gas industrial sectors, (ii) identifying and introducing potential distributors, marketing alliance and/or marketing joint-venture partners for the Company’s products within and throughout the global oil and gas industrial sectors, (iii) identifying and introducing potential merger, acquisition, or other combination target companies and/or individual business lines for the Company, (iv) identifying potential suppliers and vendors for the Company, and/or (v) identifying and introducing potential sources of strategic and related financing for the Company.

2.                    Term of Engagement.

The Engagement shall be effective for a period of twelve (12) months, commencing on the date first appearing above (the “Initial Term of Engagement”), and shall automatically renew thereafter on a month-to-month basis (“Renewal Periods”), subject to the right of the Company and/or Advisor to terminate the Engagement (“Termination”) as of the end of any given 30-day period by giving written notice to the other party at least five (5) business days prior to the end of the then-current 30-day period (the Initial Term of Engagement and any Renewal Periods shall be referred to as the “Term of Engagement”).

3.              Compensation.

In consideration for the services rendered by Advisor to the Company pursuant to the Engagement, the Company shall compensate Advisor with (i) an amount equal to eighty five thousand dollars (USD$85,000), payable in three equal cash installments of twenty eight thousand three hundred thirty three dollars (USD$28,333) on each of December 10, 2015, January 10, 2016 and February 10, 2016 and (ii) unless otherwise agreed to in writing between Advisor and the Company, a monthly retainer thereafter for each and every month that the Engagement continues in an amount equal to nine thousand five hundred dollars (USD$9,500), payable on the 30th day of each month for the month then ending.

4.              Expenses.

Unless otherwise agreed to in writing by the Company in relation to any specific expense, Advisor shall bear exclusive responsibility for all expenses incurred by him in connection with the performance of his services under this Engagement Letter and shall not be entitled to any reimbursement by the Company therefor.

 

5.                    Non-Exclusivity of Services.

It is understood and acknowledged by the Company that Advisor presently has, and anticipates having throughout the Engagement Term, other clients for which it performs the same or similar services to those to be performed in accordance herewith, and that Advisor shall be under no obligation under this Engagement to restrict its ability in any way to perform services for any other clients. It is further acknowledged that, by virtue of the nature of the services to be performed by Advisor hereunder, the value of such services bear no relation necessarily to the amount of time invested on the part of Advisor to the performance of such services, and Advisor, therefore, shall be under a continuing obligation hereunder to devote only as much time to the performance of its services hereunder as deemed appropriate in his exclusive discretion.

6.                    Indemnification.

Each party (in any given instance, an “Indemnifying Party”) hereby agrees to indemnify and hold the other party and its respective affiliates, directors, officers, employees and agents (collectively, the “Indemnified Parties”) harmless from, and to reimburse each of the Indemnified Parties for, any liability, loss, damage, deficiency, claim, obligation, suit, action, fee, cost or expense of any nature whatsoever (including, but not limited to, reasonable attorney’s fees and costs) arising out of, based upon, or resulting from any failure on its part to comply with applicable law in connection with this Engagement or the performance of its obligations under this Engagement Letter.

7.             Nature of Engagement; Limitation on Authority of Advisor to Bind.

Each of Advisor and the Company hereby acknowledge that Advisor shall perform its services hereunder as an independent contractor and not as an employee of the Company or an affiliate thereof. It is expressly understood and agreed to by the parties hereto that Advisor shall have no authority to act for, represent, or bind the Company or any affiliate thereof in any manner, except as may be agreed to expressly by the Company in writing from time to time.

8.                    Miscellaneous.

(a)                This Engagement Letter constitutes the entire agreement and understanding of the parties hereto, and supersedes any and all previous agreements and understandings, whether oral or written, between the parties with respect to the matters set forth herein.

(b)                Any notice or communication permitted or required hereunder shall be in writing and shall be deemed sufficiently given if hand-delivered or sent postage prepaid by certified mail, return receipt requested, to the other party as set forth below, or to such other address as either party may notify the other of in writing in accordance with this provision:

If to the Company, to:

Findex.com, Inc.

1313 South Killian Drive

Lake Park, FL 33403

If to Advisor, to:

J.N.B. LLC

2540 Glendale Court

Royal Palm Beach, FL 33411

(c)                This Engagement Letter shall be binding upon and inure to the benefit of each of the parties hereto and their respective successors, legal representatives and assigns.

 

(d)                No provision of this Engagement Letter may be amended, modified or waived, except in a writing signed by all of the parties hereto.

 

(e)                 This Engagement Letter shall be construed in accordance with and governed by the laws of the State of Florida, without giving effect to its conflict of law principles. The parties hereby agree that any dispute which may arise between them arising out of or in connection with this Engagement Letter shall be adjudicated before a court located in the State of Florida, and they hereby submit to the exclusive jurisdiction of the courts of the State of Florida and of the U.S. federal courts in the corresponding district with respect to any action or legal proceeding commenced by either party, and irrevocably waive any objection they now or hereafter may have respecting the venue of any such action or proceeding brought in such a court or respecting the fact that such court is an inconvenient forum, relating to or arising out of this Engagement Letter, and consent to the service of process in any such action or legal proceeding by means of certified mail, return receipt requested, care of the notice address set forth herein.

(f)            The parties hereby waive trial by jury in any action or proceeding involving, directly or indirectly, any matter arising out of or in connection with this Engagement Letter.

*     *     *    *   *   *   *

If the foregoing correctly sets forth the understanding from the perspective of the Company with respect to the foregoing, the signature of an authorized officer of the Company in the space provided below shall serve to evidence the agreement of the Company to the terms expressed herein, and cause this Engagement Letter to become a binding agreement effective as of the date on the first page hereof.

 

	 	  	 
	 	
Joseph Babcock

	 
	 	
Managing Member

	 

 

Accepted and Agreed:

FINDEX.COM, INC.

	
By:

	  	 
	
Name:

	
Steven Malone

	 
	
Title:

	
President and Chief Executive Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00251-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00251-of-00352.parquet"}]]